A total 132 patients with ALK rearrangement advanced NSCLC from 4 centers in Guangdong province, China were evaluated. All patients received crizotinib treatment...Secondly, according to the EML4-ALK rearrangement, we divided patients into variant 1, variant 3a/b, and other variant groups. The baseline characteristics of these three groups were well-balanced (Supplementary Table 2). The median PFS was similar in the three groups. In the variant 1 group the median PFS was 12.2 months (95% CI 9.2–23.5); in the variant 3a/b group, it was 12.3 months (95% CI 7.5–14.2).